Table 1. Expenditure on and access to antidiabetic, antihypertensive and antilipidemic drugs, FY 2010–2012.
| Drug | % share of OP drug expenditure (FY 2010) |
Quarterly change in drug recipients per 1,000 population* | P-value | No. of drug recipients per 1,000 population | |||||
|---|---|---|---|---|---|---|---|---|---|
| 2010 Q1 |
2010 Q3 |
2011 Q1 |
2011 Q3 |
2012 Q1 |
2012 Q3 |
||||
| Antidiabetics | |||||||||
| Insulin | 3.0% | 0.27 | <0.0001 | 3.58 | 4.35 | 4.76 | 5.39 | 5.70 | 6.27 |
| Metformin | 4.0% | 0.53 | <0.0001 | 15.81 | 18.29 | 19.31 | 19.39 | 20.57 | 21.37 |
| Glibenclamide | 1.3% | -0.20 | <0.0001 | 11.08 | 10.46 | 10.38 | 9.43 | 9.59 | 9.15 |
| Glipizide | 1.2% | 0.55 | <0.0001 | 4.03 | 5.78 | 6.77 | 7.51 | 8.42 | 9.54 |
| Pioglitazone | 0.6% | 0.14 | <0.0001 | 0.75 | 1.16 | 1.46 | 1.67 | 1.86 | 2.08 |
| Overall | 10.1% | 0.63 | <0.0001 | 21.70 | 24.58 | 25.88 | 26.06 | 27.58 | 28.75 |
| Antihypertensive agents | |||||||||
| Amlodipine | 2.5% | 1.32 | <0.0001 | 14.39 | 18.87 | 21.21 | 23.69 | 25.34 | 28.07 |
| Nifedipine | 0.6% | -0.04 | 0.0443 | 1.91 | 2.21 | 1.95 | 1.81 | 1.78 | 1.70 |
| Enalapril | 2.3% | 0.81 | 0.0002 | 20.52 | 24.54 | 26.40 | 27.03 | 27.72 | 29.31 |
| Losartan | 0.5% | 0.46 | <0.0001 | 1.56 | 2.54 | 3.40 | 4.37 | 5.11 | 6.17 |
| Overall | 5.9% | 1.79 | <0.0001 | 32.11 | 39.69 | 43.27 | 45.76 | 47.91 | 51.43 |
| Antilipidemics | |||||||||
| Simvastatin | 2.6% | 1.51 | <0.0001 | 20.84 | 25.39 | 29.02 | 31.54 | 33.67 | 35.73 |
| Atorvastatin | 2.0% | 0.03 | 0.0063 | 0.07 | 0.10 | 0.09 | 0.14 | 0.16 | 0.33 |
| Gemfibrozil | 1.2% | 0.26 | 0.001 | 6.87 | 8.36 | 9.27 | 8.80 | 9.69 | 9.51 |
| Fenofibrate | 0.2% | 0.04 | 0.0004 | 0.20 | 0.34 | 0.46 | 0.51 | 0.54 | 0.56 |
| Overall | 6.0% | 1.71 | <0.0001 | 26.78 | 32.58 | 36.87 | 39.14 | 42.17 | 44.34 |
FY, fiscal year; OP, outpatient; Q, quarter
* based on time-series analysis of 12 quarters from Q1, FY 2010 to Q4, FY 2012